9GBE
Structure of Human Anaplastic Lymphoma Kinase (ALK) harboring the G1202R/L1196M Compound Mutation in Complex with NVL-655
This is a non-PDB format compatible entry.
Summary for 9GBE
Entry DOI | 10.2210/pdb9gbe/pdb |
Descriptor | ALK tyrosine kinase receptor, NVL-655 (3 entities in total) |
Functional Keywords | alk, tyrosine kinase inhibitor, resistance, nvl-655, oncoprotein |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 1 |
Total formula weight | 39385.69 |
Authors | Mente, S.,Horan, J.C. (deposition date: 2024-07-31, release date: 2024-09-18, Last modification date: 2024-10-02) |
Primary citation | Lin, J.J.,Horan, J.C.,Tangpeerachaikul, A.,Swalduz, A.,Valdivia, A.,Johnson, M.L.,Besse, B.,Camidge, D.R.,Fujino, T.,Yoda, S.,Nguyen-Phuong, L.,Mizuta, H.,Bigot, L.,Nobre, C.,Lee, J.B.,Yu, M.R.,Mente, S.,Sun, Y.,Kohl, N.E.,Porter, J.R.,Shair, M.D.,Zhu, V.W.,Felip, E.,Cho, B.C.,Friboulet, L.,Hata, A.N.,Pelish, H.E.,Drilon, A. NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discov, :OF1-OF20, 2024 Cited by PubMed: 39269178DOI: 10.1158/2159-8290.CD-24-0231 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.58 Å) |
Structure validation
Download full validation report